Attenuation of endothelin-1-induced PKB and ERK1/2 signaling, as well as Egr-1 expression, by curcumin in A-10 vascular smooth muscle cells

Canadian Journal of Physiology and Pharmacology

Volumn 90, Issue 9, 2012, Pages 1277-1285

  Kapakos, Georgia ^a   Youreva, Viktoria ^a   Srivastava, Ashok K ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Curcumin; Early growth response 1; Endothelin 1; Extracellular signal regulated kinase 1 2; Insulin like growth factor type 1 receptor; Protein kinase b; Vascular smooth muscle cells

Indexed keywords

CURCUMIN; EARLY GROWTH RESPONSE FACTOR 1; ENDOTHELIN 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RAF PROTEIN; SOMATOMEDIN RECEPTOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA, THORACIC; APOPTOSIS; CELL CULTURE TECHNIQUES; CELL LINE; CELL PROLIFERATION; CURCUMIN; DOWN-REGULATION; EARLY GROWTH RESPONSE PROTEIN 1; ENDOTHELIN-1; MAP KINASE SIGNALING SYSTEM; MUSCLE, SMOOTH, VASCULAR; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS;

EID: 84865425705     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/Y2012-059     Document Type: Article

References (57)

1. Aggarwal, B.B., and Harikumar, K.B. 2009. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neuro-degenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell Biol. 41(1): 40-59. doi:10.1016/j.biocel.2008.06.010. PMID:18662800.
2. Ak, T., and Gulcin, I. 2008. Antioxidant and radical scavenging properties of curcumin. Chem. Biol. Interact. 174(1): 27-37. doi:10.1016/j.cbi.2008.05.003. PMID:18547552.
3. Araújo, C.C., and Leon, L.L. 2001. Biological activities of Curcuma longa L. Mem. Inst. Oswaldo Cruz, 96(5): 723-728. doi:10.1590/ S0074-02762001000500026. PMID:11500779.
4. Azar, Z.M., Mehdi, M.Z., and Srivastava, A.K. 2006. Activation of insulin-like growth factor type-1 receptor is required for H2O2-induced PKB phosphorylation in vascular smooth muscle cells. Can. J. Physiol. Pharmacol. 84(7): 777-786. doi:10.1139/y06-024. PMID:16998541.
5. Azar, Z.M., Mehdi, M.Z., and Srivastava, A.K. 2007. Insulin-like growth factor type-1 receptor transactivation in vasoactive peptide and oxidant-induced signaling pathways in vascular smooth muscle cells. Can. J. Physiol. Pharmacol. 85(1): 105-111. doi:10.1139/Y06-101. PMID:17487250.
6. Blaschke, F., Bruemmer, D., and Law, R.E. 2004. Egr-1 is a major vascular pathogenic transcription factor in atherosclerosis and restenosis. Rev. Endocr. Metab. Disord. 5(3): 249-254. doi:10.1023/B:REMD.0000032413.88756.ee. PMID:15211096.
7. Bouallegue, A., Daou, G.B., and Srivastava, A.K. 2007. Endothelin-1-induced signaling pathways in vascular smooth muscle cells. Curr. Vasc. Pharmacol. 5(1): 45-52. doi:10.2174/157016107779317161. PMID:17266612.
8. Bouallegue, A., Vardatsikos, G., and Srivastava, A.K. 2009. Role of insulin-like growth factor 1 receptor and c-Src in endothelin-1- and angiotensin II-induced PKB phosphorylation, and hypertrophic and proliferative responses in vascular smooth muscle cells. Can. J. Physiol. Pharmacol. 87(12): 1009-1018. doi:10.1139/Y09-056.PMID:20029537.
9. Chen, H.W., and Huang, H.C. 1998. Effect of curcumin on cell cycle progression and apoptosis in vascular smooth muscle cells. Br. J. Pharmacol. 124(6): 1029-1040. doi:10.1038/sj.bjp.0701914.PMID:9720770.
10. 2+-dependent Egr-1 expression and subsequently inhibits vascular smooth muscle cell proliferation induced by angiotensin II. Cell. Physiol. Biochem. 23(4-6): 295-304. doi:10.1159/000218176.PMID:19471097.
11. Daou, G.B., and Srivastava, A.K. 2004. Reactive oxygen species mediate endothelin-1-induced activation of ERK1/2, PKB, and Pyk2 signaling, as well as protein synthesis, in vascular smooth muscle cells. Free Radic. Biol. Med. 37(2): 208-215. doi:10.1016/j.freeradbiomed.2004.04.018.PMID:15203192.
12. Day, F.L., Rafty, L.A., Chesterman, C.N., and Khachigian, L.M. 1999. Angiotensin II (ATII)-inducible platelet-derived growth factor A-chain gene expression is p42/44 extracellular signal-regulated kinase-1/2 and Egr-1-dependent and mediated via the ATII type 1 but not type 2 receptor. Induction by ATII antagonized by nitric oxide. J. Biol. Chem. 274(34): 23726-23733. doi:10.1074/jbc.274.34.23726.PMID:10446131.
13. Dikshit, M., Rastogi, L., Shukla, R., and Srimal, R.C. 1995. Prevention of ischaemia-induced biochemical changes by curcu-min & quinidine in the cat heart. Indian J. Med. Res. 101: 31-35. PMID:7883281.
14. Epstein, J., Sanderson, I.R., and Macdonald, T.T. 2010. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br. J. Nutr. 103(11): 1545-1557. doi:10.1017/S0007114509993667.PMID:20100380.
15. Fahmy, R.G., and Khachigian, L.M. 2007. Suppression of growth factor expression and human vascular smooth muscle cell growth by small interfering RNA targeting EGR-1. J. Cell. Biochem. 100 (6): 1526-1535. doi:10.1002/jcb.21145.PMID:17171647.
16. Ghosh, S.S., Salloum, F.N., Abbate, A., Krieg, R., Sica, D.A., Gehr, T.W., and Kukreja, R.C. 2010. Curcumin prevents cardiac remodeling secondary to chronic renal failure through deactivation of hypertrophic signaling in rats. Am. J. Physiol. Heart Circ. Physiol. 299(4): H975-H984. doi:10.1152/ajpheart.00154.2010.PMID:20601462.
17. Harja, E., Bucciarelli, L.G., Lu, Y., Stern, D.M., Zou, Y.S., Schmidt, A.M., and Yan, S.F. 2004. Early growth response-1 promotes atherogenesis: mice deficient in early growth response-1 and apolipoprotein E display decreased atherosclerosis and vascular inflammation. Circ. Res. 94(3): 333-339. doi:10.1161/01.RES.0000112405.61577.95. PMID:14670837.
18. Hashim, S., Li, Y., and Anand-Srivastava, M.B. 2006. Small cytoplasmic domain peptides of natriuretic peptide receptor-C attenuate cell proliferation through Gia protein/MAP kinase/PI3-kinase/AKT pathways. Am. J. Physiol. Heart Circ. Physiol. 291 (6): H3144-H3153. doi:10.1152/ajpheart.00327.2006.PMID: 16920814.
19. Hlavačkova, L., Janegová, A., Uličná, O., Janega, P., Černá, A., and Babál, P. 2011. Spice up the hypertension diet - curcumin and piperine prevent remodeling of aorta in experimental l-NAME induced hypertension. Nutr. Metab. (Lond.), 8(1): 72. doi:10.1186/1743-7075-8-72.PMID:22005253.
20. Houston, P., Dickson, M.C., Ludbrook, V., White, B., Schwachtgen, J.L., McVey, J.H., et al. 1999. Fluid shear stress induction of the tissue factor promoter in vitro and in vivo is mediated by Egr-1. Arterioscler. Thromb. Vasc. Biol. 19(2): 281-289. doi:10.1161/01. ATV.19.2.281.PMID:9974408.
21. Huang, H.C., Jan, T.R., and Yeh, S.F. 1992. Inhibitory effect of curcumin, an anti-inflammatory agent, on vascular smooth muscle cell proliferation. Eur. J. Pharmacol. 221(2-3): 381-384. PMID: 426014.
22. Ivey, M.E., Osman, N., and Little, P.J. 2008. Endothelin-1 signalling in vascular smooth muscle: pathways controlling cellular functions associated with atherosclerosis. Atherosclerosis, 199(2): 237-247. doi:10.1016/j.atherosclerosis.2008.03.006.PMID:18436225.
23. Jackson, C.L., and Schwartz, S.M. 1992. Pharmacology of smooth muscle cell replication. Hypertension, 20(6): 713-736. PMID: 1452288.
24. Kang, B.Y., Khan, J.A., Ryu, S., Shekhar, R., Seung, K.B., and Mehta, J.L. 2010. Curcumin reduces angiotensin II-mediated cardiomyocyte growth via LOX-1 inhibition. J. Cardiovasc. Pharmacol. 55(2): 176-183. PMID:19935077.
25. Khachigian, L.M. 2006. Early growth response-1 in cardiovascular pathobiology. Circ. Res. 98(2): 186-191. doi:10.1161/01.RES. 0000200177.53882.c3.PMID:16456111.
26. Khachigian, L.M., Lindner, V., Williams, A.J., and Collins, T. 1996. Egr-1-induced endothelial gene expression: a common theme in vascular injury. Science, 271(5254): 1427-1431. doi:10.1126/science.271.5254.1427.PMID:8596917.
27. Levonen, A.L., Vahakangas, E., Koponen, J.K., and Yla-Herttuala, S. 2008. Antioxidant gene therapy for cardiovascular disease: current status and future perspectives. Circulation, 117(16): 2142-2150. doi:10.1161/CIRCULATIONAHA.107.718585.PMID:18427144.
28. Li, Y., Hashim, S., and Anand-Srivastava, M.B. 2006. Intracellular peptides of natriuretic peptide receptor-C inhibit vascular hypertrophy via Gqa/MAP kinase signaling pathways. Cardiovasc. Res. 72(3): 464-472. doi:10.1016/j.cardiores.2006.08.012. PMID: 17007826.
29. Li, Y., Levesque, L.O., and Anand-Srivastava, M.B. 2010. Epidermal growth factor receptor transactivation by endogenous vasoactive peptides contributes to hyperproliferation of vascular smooth muscle cells of SHR. Am. J. Physiol. Heart Circ. Physiol. 299(6): H1959-H1967. doi:10.1152/ajpheart.00526.2010.PMID: 20852045.
30. Liu, G.N., Teng, Y.X., and Yan, W. 2008a. Transfected synthetic DNA enzyme gene specifically inhibits Egr-1 gene expression and reduces neointimal hyperplasia following balloon injury in rats. Int. J. Cardiol. 129(1): 118-124. doi:10.1016/j.ijcard.2007.11.066.PMID:18242730.
31. Liu, Y., Dolence, J., Ren, J., Rao, M., and Sreejayan, N. 2008b. Inhibitory effect of dehydrozingerone on vascular smooth muscle cell function. J. Cardiovasc. Pharmacol. 52(5): 422-429. doi:10. 1097/FJC.0b013e31818aed93.PMID:19033821.
32. Liu, Q.F., Yu, H.W., and Liu, G.N. 2009. Egr-1 upregulates OPN through direct binding to its promoter and OPN upregulates Egr-1 via the ERK pathway. Mol. Cell. Biochem. 332(1-2): 77-84. doi:10.1007/s11010-009-0176-4. PMID:19557503.
33. McCaffrey, T.A., Fu, C., Du, B., Eksinar, S., Kent, K.C., Bush, H., Jr, et al. 2000. High-level expression of Egr-1 and Egr-1-inducible genes in mouse and human atherosclerosis. J. Clin. Invest. 105(5): 653-662. doi:10.1172/JCI8592. PMID:10712437.
34. Morimoto, M., Kume, N., Miyamoto, S., Ueno, Y., Kataoka, H., Minami, M., et al. 2001. Lysophosphatidylcholine induces early growth response factor-1 expression and activates the core promoter of PDGF-A chain in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 21(5): 771-776. doi:10.1161/ 01.ATV.21.5.771. PMID:11348873.
35. Morimoto, T., Sunagawa, Y., Kawamura, T., Takaya, T., Wada, H., Nagasawa, A., et al. 2008. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J. Clin. Invest. 118(3): 868-878. PMID:18292809.
36. Motte, S., McEntee, K., and Naeije, R. 2006. Endothelin receptor antagonists. Pharmacol. Ther. 110(3): 386-414. doi:10.1016/j. pharmthera.2005.08.012. PMID:16219361.
37. Nakmareong, S., Kukongviriyapan, U., Pakdeechote, P., Donpunha, W., Kukongviriyapan, V., Kongyingyoes, B., et al. 2011. Antioxidant and vascular protective effects of curcumin and tetrahydrocurcumin in rats with L-NAME-induced hypertension. Naunyn Schmiedebergs Arch. Pharmacol. 383(5): 519-529. doi:10.1007/s00210-011-0624-z. PMID:21448566.
38. Neyses, L., Nouskas, J., and Vetter, H. 1991. Inhibition of endothelin-1 induced myocardial protein synthesis by an antisense oligonu-cleotide against the early growth response gene-1. Biochem. Biophys. Res. Commun. 181(1): 22-27. doi:10.1016/S0006-291X (05)81376-2. PMID:1958190.
39. Nirmala, C., and Puvanakrishnan, R. 1996. Protective role of curcumin against isoproterenol induced myocardial infarction in rats. Mol. Cell. Biochem. 159(2): 85-93. doi:10.1007/ BF00420910. PMID:8858558.
40. Pae, H.O., Jeong, G.S., Jeong, S.O., Kim, H.S., Kim, S.A., Kim, Y.C., et al. 2007. Roles of heme oxygenase-1 in curcumin-induced growth inhibition in rat smooth muscle cells. Exp. Mol. Med. 39 (3): 267-277. PMID:17603281.
41. Pirvulescu, M.M., Gan, A.M., Stan, D., Simion, V., Calin, M., Butoi, E., et al. 2011. Curcumin and a Morus alba extract reduce pro-inflammatory effects of resistin in human endothelial cells. Phytother. Res. 25(12): 1737-1742. doi:10.1002/ptr.3463. PMID: 21442673.
42. Qin, L., Yang, Y.B., Tuo, Q.H., Zhu, B.Y., Chen, L.X., Zhang, L., and Liao, D.F. 2009. Effects and underlying mechanisms of curcumin on the proliferation of vascular smooth muscle cells induced by Chol:MbetaCD. Biochem. Biophys. Res. Commun. 379(2): 277-282. doi:10.1016/j.bbrc.2008.12.038. PMID: 19101502.
43. Ramirez, B.A., Soler, A., Carrion-Gutierrez, M.A., Pamies, M.D., Pardo, Z.J., Diaz-Alperi, J., et al. 2000. An hydroalcoholic extract of Curcuma longa lowers the abnormally high values of human-plasma fibrinogen. Mech. Ageing Dev. 114(3): 207-210. doi:10.1016/S0047-6374(00)00089-0. PMID:10802125.
44. Reddy, A.C., and Lokesh, B.R. 1994. Studies on the inhibitory effects of curcumin and eugenol on the formation of reactive oxygen species and the oxidation of ferrous iron. Mol. Cell. Biochem. 137 (1): 1-8. doi:10.1007/BF00926033. PMID:7845373.
45. Reriani, M., Raichlin, E., Prasad, A., Mathew, V., Pumper, G.M., Nelson, R.E., et al. 2010. Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis. Circulation, 122(10): 958-966. doi:10.1161/CIRCULATIONAHA.110.967406. PMID:20733096.
46. Shankar, S., and Srivastava, R.K. 2007. Involvement of Bcl-2 family members, phosphatidylinositol 3′-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Int. J. Oncol. 30(4): 905-918. PMID:17332930.
47. Sharma, O.P. 1976. Antioxidant activity of curcumin and related compounds. Biochem. Pharmacol. 25(15): 1811-1812. doi:10.1016/0006-2952(76)90421-4. PMID:942483.
48. Shen, L., and Ji, H.F. 2009. Insights into the inhibition of xanthine oxidase by curcumin. Bioorg. Med. Chem. Lett. 19(21): 5990-5993. doi:10.1016/j.bmcl.2009.09.076. PMID:19800788.
49. Shishodia, S., Singh, T., and Chaturvedi, M.M. 2007. Modulation of transcription factors by curcumin. Adv. Exp. Med. Biol. 595: 127-148. doi:10.1007/978-0-387-46401-5_4. PMID:17569208.
50. Soni, K.B., and Kuttan, R. 1992. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J. Physiol. Pharmacol. 36(4): 273-275. PMID:1291482.
51. Sreejayan, and Rao, M.N. 1994. Curcuminoids as potent inhibitors of lipid peroxidation. J. Pharm. Pharmacol. 46(12): 1013-1016. doi:10.1111/j.2042-7158.1994.tb03258.x. PMID:7714712.
52. Touyz, R.M., and Schiffrin, E.L. 2003. Role of endothelin in human hypertension. Can. J. Physiol. Pharmacol. 81(6): 533-541. doi:10. 1139/y03-009. PMID:12839265.
53. Venkatesan, N. 1998. Curcumin attenuation of acute adriamycin myocardial toxicity in rats. Br. J. Pharmacol. 124(3): 425-427. doi:10.1038/sj.bjp.0701877. PMID:9647462.
54. Yang, X., Thomas, D.P., Zhang, X., Culver, B.W., Alexander, B.M., Murdoch, W.J., et al. 2006. Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation. Arterioscler. Thromb. Vasc. Biol. 26(1): 85-90. doi:10.1161/01.ATV.0000191635.00744.b6. PMID:16239599.
55. Yu, Y.M., and Lin, H.C. 2010. Curcumin prevents human aortic smooth muscle cells migration by inhibiting of MMP-9 expression. Nutr. Metab. Cardiovasc. Dis. 20(2): 125-132. doi:10.1016/j. numecd.2009.03.001. PMID:19447587.
56. Zhang, Y.M., Shi, G.G., Tang, Z., Zheng, J.H., Li, W.Q., Guo, F.X., and Jia, Q.Y. 2006. Effects of N-n-butyl haloperidol iodide on myocardial ischemia/reperfusion injury and Egr-1 expression in rat. Acta Biochim. Biophys. Sin. (Shanghai), 38(6): 435-441. doi:10.1111/j.1745-7270.2006.00180.x. PMID:16761102.
57. Zhou, H., Beevers, C.S., and Huang, S. 2010. The targets of curcumin. Curr. Drug Targets, 12(3): 332-347. PMID:20955148.